“There are a lot of risks,” he said.
Bosh experienced his first known clotting problem in February 2015. He had cramps, spasms and shortness of breath, although he tried to hide his symptoms, he said. Bosh recalled one particular instance when he was in pain until 3 or 4 in the morning and the Heat were scheduled to face the Dallas Mavericks the following day. Bosh played because the Heat were already short-handed.
“Not the best thing to do,” Bosh said on the podcast, adding: “One thing about athletes — and I don’t know what it is about us — we ignore pain, or we try our best to ignore pain. And I think that’s one of the worst things you can possibly do.”
Bosh was eventually hospitalized, and tests revealed that a blood clot in his calf had traveled to his lungs, causing a pulmonary embolism — a serious condition that can be fatal. Bosh had surgery and spent nine days in a hospital. He lost 20 to 25 pounds, he said, and missed the final 30 games of the 2014-15 season.
Bosh has never publicly articulated his specific course of treatment, but he presumably took blood-thinning drugs. He appeared in a television commercial for one such medication, Xarelto.
Bosh was cleared by the Heat to return for the 2015-16 season opener. He played well through the first half of the season, averaging 19.1 points and 7.4 rebounds per game before the All-Star break. But a few days before the All-Star Game, he awoke with a sore calf. He was soon found to have a recurrence of blood clots. He met with team doctors, who told him that his season was over and that his career was probably finished, too, he said.
“I felt right away that I was written off,” Bosh said in one of his interviews with Uninterrupted. He added, “If a doctor tells me, ‘Hey, that’s it, and this is how it is,’ and I don’t buy that, then I think I have the right to disagree with you.”
Bosh also alluded to the tension between himself and the Heat’s medical staff.
“If you’re an athlete in this game, you have to protect your own interests, and you have to protect your body and your family,” Bosh said. “If one doctor is a doctor for 15 guys, who’s paying this guy?”
He added, “If you’re paying a doctor through your pocket, your insurance — whatever that case may be — that changes their interest.”
It has mostly remained a one-sided public tussle. The Heat, aside from sporadic statements, have not spoken in detail about Bosh’s medical situation, nor have team officials said what liability, if any, the franchise might have if something were to happen to Bosh on the court.
The Heat’s president, Pat Riley, told reporters on Monday that Bosh’s career with the team “is probably over.”
“There is not a next step for us,” Riley said. “It’s pretty definitive for us in our position.”
The Heat declined interview requests for this article. The players’ union did not immediately return a call seeking comment.
Samantha Brennan, a philosophy professor at Western University in London, Ontario, teaches a class on sports ethics that touches on the role of team doctors and the conflicts of interest that can arise — namely, clearing athletes to return to competition before they are ready.
“That’s what makes the case involving Chris Bosh so unusual,” Brennan said, referring to the prevailing urge among teams to send players back onto the field.
So what happens if an athlete, fully aware of the medical risks, insists on continuing to play? Does the team have a moral responsibility to look out for the athlete’s well-being? In most cases, Brennan said, risk taking is left to the discretion of adults. The challenge with many athletes, she said, is that they have invested so much of themselves in their careers from an early age that it can cloud their judgment.
“When they need to make a difficult decision, it puts them in a bind,” Brennan said. “It makes it very hard for them to say, ‘I’m ready to stop playing.’”
Ultimately, Brennan said, an athlete is an employee, and team officials have the power to do what they want.
“So they’re making two kinds of decisions,” Brennan said, referring to the Heat. “One is an ethical decision about not wanting someone they know and care about — imagine if he died playing. They’re also making a self-interested decision because they’re worried about injuries and liability.”
Dr. Jack Ansell, a professor of medicine at Hofstra Northwell School of Medicine on Long Island, said he knew of several athletes who had managed blood-clot problems by taking blood thinners between games and then allowing the medication to be flushed from their systems before they returned to competition.
Ansell, a member and former chairman of the medical and scientific advisory board of the National Blood Clot Alliance, has not examined Bosh and has no specific knowledge of his case. But Ansell said he suspected that Bosh would need long-term blood-thinning therapy to prevent recurring clots and that the grueling schedule of the N.B.A. would make intermittent treatment difficult.
“You’re playing games every two or three nights,” he said, “so there’s no real time off.”
Rebekah Bradford Plath, a speedskater who competed at the 2010 Winter Olympics, developed a pulmonary embolism in 2012. While still on blood-thinning therapy, she resumed training. The risks were fairly minimal. Long-track speedskating is a noncontact sport, although falls do happen; Bradford Plath wore a helmet.
“I do know that I probably made some of my teammates nervous when they were skating around me,” she said in a telephone interview. “Some of them understood the significance of what I was doing. But I trusted my ability, I trusted the ability of my teammates, and I felt comfortable and confident.”
Last year, after having knee surgery, Bradford Plath had a recurrence of blood clotting even though she was taking blood thinners at the time. After her physician increased the dosage, she said, the clot cleared.
Bradford Plath, who still takes blood thinners when she travels on airplanes, continues to train with an eye on the 2018 Winter Olympics.